BioWorld

May 23, 2006

Adventrx Moves Into Phase III With CoFactor, Pulls Offering

Adventrx Pharmaceuticals Inc. and the FDA have agreed on a special protocol assessment for a Phase III trial of its chemotherapy enhancing drug, CoFactor, expected to start this quarter. (BioWorld Today) Read More

U3 Pharma Raises €27M For Preclinical Cancer Products

No Abstract Read More

ImaRx Seeking $75M IPO For Anti-Clotting Products

SEC Signaling Interest In Scaling Back SOX Rules

Naryx Series B2 Financing Gets $8M For Chronic Sinusitis Drug

Clinic Roundup

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 26, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 27, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Muted and missing M&As: JPM deals absent in 2026

BioWorld

For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...